Immune checkpoint inhibitors (ICIs) target receptors such as programmed cell death protein 1 (PD-1) on T-cell lymphocytes or programmed death-ligand 1 (PD-L1) on tumor cells and optimize antitumor microenvironments via inhibition of checkpoint signaling pathways. This evidence concerns the gene CD274 and neoplasm.